Antidepressant drug trials turn away most of the depressed population

February 28, 2002

PROVIDENCE, R.I. -- While antidepressants are among the most frequently prescribed medications, most patients treated for major depression in a typical outpatient psychiatric practice would not qualify to take part in a clinical trial for a new antidepressant drug, according to a new Brown University study.

Trials to determine the effectiveness of antidepressants have historically evaluated only a small subset of depressed individuals with a very specific clinical profile. People diagnosed with other psychiatric problems and people with mild depression are among those excluded, says the study, which appears in the March 2002 American Journal of Psychiatry.

"When you take any medicine you assume it's been found to be effective for your condition," said Mark Zimmerman, associate professor of psychiatry and human behavior, director of outpatient psychiatry at Rhode Island Hospital, and the study's lead researcher. "No one knows for sure whether antidepressants are effective for most of the patients we treat."

As few as 15 percent of 346 depressed patients evaluated in the Rhode Island Hospital Department of Psychiatry outpatient clinic would have met the eligibility requirements of a standard drug trial, depending on the criteria.

To determine whether the clinic patients would qualify for the drug studies, the researchers reviewed inclusion and exclusion criteria used in 31 antidepressant trials published from 1994 to 1998 in five leading psychiatric journals. Many of the studies excluded patients who had psychotic features, a history of manic episodes, suicide risk, unstable medical illnesses, or a history of drug or alcohol abuse. Several also excluded subjects with eating disorders, obsessive-compulsive disorder or panic disorder.

Nearly all of the studies excluded patients who fell below a cutoff score on a measure of symptom severity, even though they were diagnosed with major depression. "We are not aware of any other medical condition in which individuals with the disorder are routinely excluded because they are not sick enough," said Zimmerman.

"Drug companies are concerned that individuals with mild depression will respond just as well to a placebo as they will to antidepressant medication," said Zimmerman. "However, this represents a sizable number of individuals who are prescribed these medicines, especially by primary care physicians."

The researchers conducted diagnostic evaluations of patients at the Rhode Island Hospital Department of Psychiatry outpatient practice, a group ranging in age from 16 to 65. Excluding patients with any of the features commonly used in efficacy trials eliminated two-thirds of the patients. If patients with an anxiety disorder were also excluded, then more than 85 percent of the patients would not have qualified for a drug study of antidepressants - yet more than 90 percent of the patients in the study for whom prescribing information was available were being treated with antidepressants at the time of the evaluation.

Some extrapolation of antidepressant studies by clinicians will always be necessary, Zimmerman said. It would be impossible to establish the effectiveness of antidepressant medications in every conceivable population of depressed patients. But the current practice of limiting studies to only "pure" moderate-to-severely ill depressives may skew the findings of drug trials, he added. If antidepressants are, in fact, not effective for some of these large subgroups of depressed individuals, their prescription incurs an unjustifiable exposure of risks and side effects, and alternative treatments need to be considered.

Opening antidepressant trials to patients with a wider range of symptoms would allow researchers to learn whether any specific subsets respond or do not respond to a drug. The question now is whether government mandates are necessary to make trials more inclusive, Zimmerman said. There is little motivation for drug companies - whose primary aim is to show that their medication is safe and that it works for some patients - to do this.

"Drug companies have been correct in assuming that if they show their medicine works for a highly select group of depressed patients, physicians will use it for all patients," said Zimmerman.
-end-
This study was supported by grants from the National Institutes of Mental Health. Zimmerman worked with Jill I. Mattia, clinical assistant professor, and Michael A. Posternak, research fellow, in the Department of Psychiatry and Human Behavior at Brown University.

Brown University

Related Antidepressants Articles from Brightsurf:

Measuring brainwaves while sleeping can tell if you should switch antidepressants
Scientists have discovered that measuring brainwaves produced during REM sleep can predict whether a patient will respond to treatment from depression.

Antibodies: the body's own antidepressants
Antibodies can be a blessing or a curse to the brain -- it all depends on their concentration.

Are some antidepressants less risky for pregnant women?
About one in ten women in Qu├ębec will suffer from depression during pregnancy.

The effect of taking antidepressants during pregnancy
Exposure to antidepressants during pregnancy and the first weeks of life can alter sensory processing well into adulthood, according to research in mice recently published in eNeuro.

Significantly fewer pregnant women take antidepressants
A pregnancy is not always a happy event and as many as 10-15% of pregnant women in Denmark have depressive symptoms.

Antidepressants reduce deaths by more than a third in patients with diabetes
Antidepressants reduce deaths by more than a third in patients with diabetes and depression, according to a study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

Antidepressants can reduce the empathic empathy
Depression is a disorder that often comes along with strong impairments of social functioning.

Possible link between autism and antidepressants use during pregnancy
An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in the womb.

When neurons are out of shape, antidepressants may not work
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed medication for major depressive disorder (MDD), yet scientists still do not understand why the treatment does not work in nearly thirty percent of patients with MDD.

Next-generation metabolomics may facilitate the discovery of new antidepressants
Antidepressants have become one of the most commonly prescribed drugs.

Read More: Antidepressants News and Antidepressants Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.